Chart Events
Performance Outlook
| Previous Close | 85.30 |
| Open | 85.30 |
| Bid | 84.20 x 0 |
| Ask | 84.90 x 0 |
| Day's Range | 84.20 - 85.30 |
| 52 Week Range | 0.63 - 114.00 |
| Volume | 45,076 |
| Avg. Volume | 25,073 |
| Market Cap | 43.082M |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.42 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Cannasure and DanCann Pharma sign an exclusive distribution agreement for Denmark, Norway, Sweden and Finland
Cannassure Therapeutics Ltd (TASE: CSURE) ("Cannassure"), an Israel based developer and producer of innovative medical cannabis products, announces today the singing of an exclusive distribution agreement with DannCan Pharma. Under the agreement, Dancann will distribute Cannasure's medical cannabis products in Denmark, Norway, Sweden and Finland. The specific products, as well as the branding will be determined mutually by both parties.
- PR Newswire
Successful completion of feasibility study for the development of topical medical cannabis products based on AKVANO® technology
Cannassure Therapeutics Ltd (TASE: CSURE) ("Cannassure"), an Israel based developer and producer of innovative medical cannabis products, announces today the successful completion of a feasibility study for the development of IP protected, homogeneous, topical medical Cannabis products for the treatment of skin inflammation, including psoriatic lesions.
